Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tysabri

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

- PMLiVE

Biogen’s R&D chief Ehlers heads for the exit

Follows multiple late-stage Alzheimer's study failures

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

- PMLiVE

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Ranitidine medicines found to contain cancer-causing substance

- PMLiVE

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

Amgen wins Enbrel patent case, knocking back Sandoz’s biosimilar plan

Shares up 6% following court ruling

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links